<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02695433</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2016-001</org_study_id>
    <nct_id>NCT02695433</nct_id>
  </id_info>
  <brief_title>Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers</brief_title>
  <acronym>AV2</acronym>
  <official_title>Effects of a Typical American Diet High in Refined Carbohydrates Compared to a Diet That Replaces Some Refined Carbohydrates With Healthy Fats on Cardiometabolic Health in Men and Women With Pre-diabetes and Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Nutrition Research Center, Illinois Institute of Technology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Nutrition Research Center, Illinois Institute of Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal is to to characterize the effects of consuming 1 avocado fruit 7 days / week&#xD;
      (5-7 days is acceptable) compared to a no avocado relatively low fat, carbohydrate control&#xD;
      treatment over a 12 week period on insulin sensitivity as measured by the Matsuda composite&#xD;
      index of insulin sensitivity (MISI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is designed as a randomized, controlled, statistician blinded, 2-arm parallel study&#xD;
      to investigate the effects of avocado consumption compared to non-avocado control foods which&#xD;
      have opposing macronutrients (avocado is relatively higher in fat and in low carbohydrate and&#xD;
      the control foods will be low fat, high carbohydrate options) on indices of cardiometabolic&#xD;
      health over a 12 week period.&#xD;
&#xD;
      The trial will test 2 treatment conditions in pre-diabetic men and women 25-60 years of age&#xD;
      with metabolic syndrome. One hundred twenty men and women will be recruited, aiming for a&#xD;
      completer set of 96 subjects. Qualified Subjects will be randomized to receive 1 of 2 test&#xD;
      treatments based on randomization schedule from a computer generated randomization schedule.&#xD;
&#xD;
      Study treatments include:&#xD;
&#xD;
        -  Control (CT) diet plan with at least 1 serving of a low fat, low fiber, high glycemic&#xD;
           carbohydrate and eliminate avocado 7 days / week (5-7 days is acceptable) over a 12 week&#xD;
           period.&#xD;
&#xD;
        -  Active treatment (AT) diet plan will include 1 Avocado 7 days/week (5-7 days is&#xD;
           acceptable) over a 12 week period.&#xD;
&#xD;
      Each subject will be asked to come for one Screening Visit, 9 interim food pick-up/compliance&#xD;
      visits and 4 Test Day Visits. The four main Test Day visits will occur at week 0 (day 1;&#xD;
      baseline), end of week 4, at the end of week 8 and at the end of week 12. Interim Visits will&#xD;
      occur at week 1, 2, 3, 5, 6, 7, 9, 10 and 11. Subjects will pick-up study foods, answer&#xD;
      questionnaires, receive dietary counseling, confirm diet compliance during interim visits.&#xD;
      They will also be asked to complete online 24 hour food recalls up to once per each week of&#xD;
      the study. Each of the 4 Test Day Visits will last about 2-3.5 h and involve blood pressure&#xD;
      (BP) measurements, a fasting blood sample collection and anthropometric, body composition&#xD;
      assessment. In addition, an oral glucose tolerance test (OGTT) will be performed at week&#xD;
      0/day 1 and at the end of week 12/day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">May 15, 2021</completion_date>
  <primary_completion_date type="Actual">January 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI) in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>insulin sensitivity as measured by the Matsuda composite index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood glucose response in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>fasting blood glucose response in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood insulin response in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>fasting blood insulin response in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting HbA1c response in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>fasting HbA1c response in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>blood pressure in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood Triglycerides concentration in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>fasting blood Triglycerides concentration in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting hs C-Reactive Protein in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>fasting hs C-Reactive Protein in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting markers of endothelial dysfunction (ICAM-1) in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>fasting markers of endothelial dysfunction (ICAM-1) in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting markers of endothelial dysfunction (VCAM-1) in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>fasting markers of endothelial dysfunction (VCAM-1) in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in attitudes towards eating measured by the Stunkard 3-Factor Eating Questionnaire in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>attitudes towards eating measured by the Stunkard 3-Factor Eating Questionnaire in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma LDL cholesterol in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>plasma LDL cholesterol in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma total cholesterol in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>plasma total cholesterol in 12-week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>plasma HDL cholesterol in 12-week intervention</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in body weight in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>body weight in 12-week intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in waist circumference in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>waist circumference in 12-week intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in body composition in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>body composition in 12-week intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood lipoproteins in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Changes in lipoprotein particle size/density by nuclear magnetic resonance (NMR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood IL-6 in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>blood IL-6 in 12-week intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood MCP-1 in 12-week intervention of active treatment vs control treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>blood MCP-1 in 12-week intervention</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Pre-diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Active treatment (AT) diet plan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Avocado 7 days/week (5-7 days is acceptable) over a 12 week period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (CT) diet plan</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>at least 1 serving of a low fat, low fiber, high glycemic carbohydrate and eliminate avocado 7 days / week (5-7 days is acceptable) over a 12 week period</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active</intervention_name>
    <description>Active Treatment Diet Plan</description>
    <arm_group_label>Active treatment (AT) diet plan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Control Diet Plan</description>
    <arm_group_label>Control (CT) diet plan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 25-65 yrs.&#xD;
&#xD;
          -  BMI of 25 - 42 kg/m2&#xD;
&#xD;
          -  HOMA-IR â‰¥ 2&#xD;
&#xD;
          -  Abdominal obesity: mid-point waist circumference &gt;102 cm for men and &gt;88 cm for women&#xD;
&#xD;
          -  No clinical evidence / history of heart disease, respiratory, renal, gastrointestinal,&#xD;
             or hepatic disease&#xD;
&#xD;
          -  Not taking over-the-counter or prescription medications/dietary supplements that may&#xD;
             interfere with study procedures or endpoints (e.g., antioxidant supplements, protein&#xD;
             powder, energy drinks, anti-inflammatory or lipid-lowering medications).&#xD;
&#xD;
          -  Non-smoker or past smoker (smoking cessation &gt; 2 yrs.)&#xD;
&#xD;
          -  Able to provide informed consent and comply with study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Aged &lt; 25 or &gt; 65 years&#xD;
&#xD;
          -  BMI &lt; 25 kg/m2 or &gt; 42 kg/m2&#xD;
&#xD;
          -  HOMA-IR &lt; 2.0&#xD;
&#xD;
          -  History of heart disease, respiratory, renal, gastrointestinal or hepatic disease&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Have or had cancer other than non-melanoma skin cancer in past 5 years&#xD;
&#xD;
          -  Taking over-the-counter or prescription medications or dietary supplements that may&#xD;
             interfere with study procedures or endpoints (including protein powers, energy drinks)&#xD;
&#xD;
          -  Vegan dietary habits, unusual dietary habits or sensitive or allergic to any of the&#xD;
             test meal components / ingredients&#xD;
&#xD;
          -  Consuming 3 or more avocados per week.&#xD;
&#xD;
          -  Consuming 3 or more servings of nuts or peanuts per week, unless subject is willing to&#xD;
             stop consuming nuts 4 weeks before and throughout the course of the study.&#xD;
&#xD;
          -  Excessive coffee and tea consumers (&gt;4 cups/day)&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Actively losing weight or trying to lose weight (unstable body weight fluctuations of&#xD;
             &gt; 5 kg in 3 months&#xD;
&#xD;
          -  Drug or alcohol addiction&#xD;
&#xD;
          -  Present with significant psychiatric or neurological disturbances&#xD;
&#xD;
          -  Working overnight (e.g 3rd shift of overnight workers)&#xD;
&#xD;
          -  Pregnant, lactating or planning to become pregnant&#xD;
&#xD;
          -  Have donated blood within 3 months of the screening visit and blood&#xD;
             donors/participants for whom participation in this study will result in having donated&#xD;
             more than 1500 milliliters of blood in the previous 12 months.&#xD;
&#xD;
          -  Women who are taking unstable dose and brand of hormonal contraceptive and/or stable&#xD;
             dose and brand less than 6 months&#xD;
&#xD;
          -  Excessive exercisers or trained athletes&#xD;
&#xD;
          -  Take part in chronic feeding or medication clinical trial in the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britt Britt Burton-Freeman, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Illinois Institute of Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Nutrition Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2016</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-diabetes</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Matsuda composite index of insulin sensitivity (MISI)</keyword>
  <keyword>Blood glucose</keyword>
  <keyword>Insulin response</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Lipid</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

